Clinical trial
Effect of Atomoxetine and DAW2022 on OSA Severity
NCT05350215 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Atomoxetine and DAW2022 on OSA Severity
- Lead sponsor
- Brigham and Women's Hospital
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- June 1, 2022
- Completion date
- December 1, 2026
- Enrollment
- 18 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
obstructive sleep apnea